First Immunotherapy Receives FDA Approval for Breast Cancer Treatment

In this article
On 8 March 2019, the United States Food and Drug Administration (FDA), for PD-L1-positive, unresectable locally advanced or metastatic disease in triple-negative breast cancer as first-line treatment, nab-paclitaxel chemotherapy combined with an immunotherapy drug, atezolizumab (Tecentriq), received accelerated approval.
Note: Of breast cancers, % 15 Are Approximately Triple-Negative Breast Cancer.
Atezolizumab became the first immunotherapy drug approved for treating breast cancer.
The new approval was based on results presented at ESMO 2018 from the IMpassion130 named clinical trial progression-free (without progression) survival (progression-free survival, PFS) results.
The study enrolled 902 patients with unresectable locally advanced or metastatic triple-negative breast cancer. Patients were randomly assigned to two arms: 451 received atezolizumab plus nap-paclitaxel, while the other 451 received placebo plus nab-paclitaxel.
Results of the IMpassion130 Study
In the overall patient group, median progression-free survival was 7.2 months when atezolizumab was added to chemotherapy, compared with 5.5 months in the placebo plus chemotherapy arm.
Atezolizumab also increased median overall survival, but statistical significance was not reached at the interim analysis (21.3 and 17.6 months).
Researchers also performed a subgroup analysis among patients with tumor-infiltrating immune system cells showing PD-L1 levels ≥ % 1. Among patients with triple-negative breast cancer, approximately % 40 had PD-L1 positivity . This analysis included 185 patients in the atezolizumab group and 184 in the placebo group.
The study’s most striking results were in this PD-L1-positive group;
- Atezolizumab significantly reduced the risk of disease progression or death.
- Median progression-free survival was 7.5 months in the immunotherapy arm and 5.0 months in the placebo arm.
- Adding immunotherapy to chemotherapy reduced the risk of progression by % 38.
- The objective response rate was % 53 in the immunotherapy arm and % 33 in the placebo arm.
- Immunotherapy also prolonged median overall survival: 25.0 months versus 15.5 months.
Following these striking findings, immunotherapy plus chemotherapy may become the new standard for PD-L1-positive triple-negative breast cancer. However, it is too early to draw a definitive conclusion because overall survival data for this combination are not yet fully mature.
Administration and Dose:
Atezolizumab was given in every 28-day cycle on days 1 and 15 by intravenous (IV) infusion at a fixed dose of 840 mg over 60 minutes, until disease progression or unacceptable adverse effects. Following immunotherapy, nab-paclitaxel was given in every 28-day cycle on days 1., 8., and 15. by IV infusion at an initial dose of 100 mg / m2.
During the study, progression or death occurred in 358 patients (% 79,4) in the atezolizumab group and 378 (% 83,8) in the placebo group.
Adverse Effects
Researchers reported that adverse effects were consistent with the safety profiles of the study drugs; atezolizumab plus nab-paclitaxel produced no new safety signals.
Serious adverse effects were reported in % 23 of the atezolizumab group and % 18 of the placebo group (grade 3. and 4.). The most common serious adverse effects were neutropenia (% 8); peripheral neuropathy (% 6); fatigue (% 4); and anemia (% 3).
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.